Share on StockTwits

MedAssets (NASDAQ:MDAS) Director Terrence J. Mulligan sold 1,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $22.93, for a total transaction of $22,930.00. Following the completion of the sale, the director now directly owns 927 shares in the company, valued at approximately $21,256. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

MedAssets (NASDAQ:MDAS) traded down 1.89% on Wednesday, hitting $22.80. 336,355 shares of the company’s stock traded hands. MedAssets has a one year low of $16.31 and a one year high of $26.58. The stock’s 50-day moving average is $23.71 and its 200-day moving average is $22.34. The company has a market cap of $1.390 billion and a P/E ratio of 52.82.

MedAssets (NASDAQ:MDAS) last announced its earnings results on Wednesday, April 30th. The company reported $0.32 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.33 by $0.01. On average, analysts predict that MedAssets will post $1.37 earnings per share for the current fiscal year.

A number of research firms have recently commented on MDAS. Analysts at Raymond James reiterated an “outperform” rating on shares of MedAssets in a research note on Thursday, May 1st. They now have a $25.00 price target on the stock. Separately, analysts at Sterne Agee reiterated a “buy” rating on shares of MedAssets in a research note on Thursday, May 1st. They now have a $29.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of MedAssets in a research note on Thursday, May 1st. They now have a $22.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $25.75.

MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.